Introduction:
The global biosimilar market is rapidly evolving, with an increasing focus on patient registries to track and monitor the usage and efficacy of biosimilar products. In 2026, the spotlight is on the top 50 major biosimilar patient registries worldwide, reflecting the growing importance of real-world data in the pharmaceutical industry. With the market size of biosimilars expected to reach $35 billion by 2026, these patient registries play a crucial role in providing valuable insights into the safety and effectiveness of these products.
Top 50 Major Biosimilar Patient Registries Worldwide 2026:
1. United States – With over 10 million patients enrolled in various biosimilar patient registries, the US leads the way in tracking the real-world outcomes of biosimilar treatments.
2. Germany – As a key player in the biosimilar market, Germany boasts a comprehensive patient registry system that covers a wide range of biosimilar products.
3. Japan – With a focus on ensuring the safety and efficacy of biosimilars, Japan has established several patient registries to monitor the usage of these products.
4. United Kingdom – The UK has implemented a centralized patient registry system for biosimilars, providing valuable data for healthcare professionals and regulators.
5. France – Known for its stringent regulatory framework, France has developed robust patient registries to assess the performance of biosimilar treatments.
6. South Korea – As a leading market for biosimilars, South Korea has invested heavily in patient registries to track the adoption and outcomes of these products.
7. Italy – With a growing demand for biosimilars, Italy has set up several patient registries to monitor the utilization of these treatments.
8. Spain – Spain has established national patient registries for biosimilars, enabling healthcare providers to track the real-world effectiveness of these products.
9. Canada – With a focus on promoting access to biosimilars, Canada has implemented patient registries to evaluate the impact of these treatments on patient outcomes.
10. Australia – Known for its innovative healthcare system, Australia has developed patient registries to assess the safety and efficacy of biosimilar therapies.
Insights:
The growing number of biosimilar patient registries worldwide reflects the increasing importance of real-world data in evaluating the performance of these products. With biosimilars projected to account for 28% of the global biologics market by 2026, patient registries play a crucial role in monitoring the safety, efficacy, and cost-effectiveness of these treatments. By analyzing the data collected from these registries, healthcare providers and regulators can make informed decisions about the use of biosimilars, ultimately leading to improved patient outcomes and cost savings in the healthcare system.
Related Analysis: View Previous Industry Report
